Interestingly, type I and type IV tumours showed improved disease-free survival; however, type II tumours (PD-L1 negative tumours with low TIL level) were associated with poor disease-free survival, and type III tumours had intermediate disease-free survival rates in HR−/HER2+ breast cancers, although it was not statistically significant. This evidence concerns the gene ERBB2 and breast cancer.